Randomized controlled trialHumanClinical Trial, Phase III
Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes
The New England journal of medicine, 2025 Aug 14. Davies MJ, Bajaj HS, Broholm C and 8 others.
Study type
Randomized controlled trial · Clinical Trial, Phase III
Subjects
Human participants (PubMed MeSH: Humans)
Journal
The New England journal of medicine
Published
2025 Aug 14
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
AdultAgedFemaleHumansMaleMiddle AgedBlood GlucoseBody Mass IndexDiabetes Mellitus, Type 2Double-Blind MethodGlycated HemoglobinHypoglycemia
Other papers on CagriSema
Randomized controlled trial · 2026
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial
Randomized controlled trial · 2025Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page